DESCRIPTION (provided by applicant): MYC is the most frequently amplified gene in human cancer and is overexpressed as a consequence of mutations in diverse oncogenic signaling pathways. This proposal will address key questions to resolve the mechanism of MYC transcriptional activation, explore the structure of the unique MYC transactivation domain, and study the impact of mRNA cap methylation which may mediate MYC activities as much or more than transcription. Given the central role of MYC in cancer biology, each of these interrelated goals will offer important new insight into the growth of cancer cells and how this may differ from
normal cells. Aim 1: How does MYC activate transcription? The best characterized MYC cofactor is TRRAP, which links MYC to two large acetyltransferase complexes. We will define the genome wide role of this mechanism in MYC-dependent transcriptional activation and identify the substrate(s) of acetylation. Alternatively, we will explore direct MYC-dependent recruitment of the TFIIH and/or PTEFb kinase complexes which regulate RNA polymerase II initiation and elongation. Aim 2: How does MYC enhance mRNA cap methylation? We discovered that MYC can regulate mRNA cap methylation over and above its role in transcriptional activation. This finding has broad ramifications for our understanding of MYC responsive genes since the net effect of increased cap methylation is significantly greater than transcriptional induction for every target gene analyzed. We will use eIF4E-beads to provide a comprehensive assessment of differential cap methylation. We will also define the interactions between MYC, the cap methyltransferase (RNMT) and the RNAPII CTD that are the likely mediators of the activity. Finally, we will explore a broader role for differential cap methylationin other important signaling pathways. Aim 3: What is the structure of the unique MYC transactivation domain? The structure of the DNA binding domain was determined many years ago, but little is known about the structure of the MYC transactivation domain, an unanswered question for most transcription factors. We hypothesize that the transactivation domain may acquire a defined structure in complex with a key transcriptional cofactor, TRRAP. The MYC transactivation domain, especially the essential MBII motif, is highly unique and nearly invariant in evolution and could be a target for specific inhibitors of MYC function, in contrast to the heli-loop-helix/leucine-zipper domains that are shared by over 100 other transcription factors.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE: Cancer is one of the leading causes of death worldwide, and mutations in the gene called c-myc are found in 15-20% of all cancer. Myc functions by binding to DNA and regulating other genes, but how it achieves this remains poorly understood. The goal of this project is to determine which cellular proteins associate tightly with Myc and how these Myc-associated proteins mediate Myc regulatory activity. A better understanding of Myc function will open new avenues for the diagnosis and treatment of cancer.
NIH Spending Category
CancerCancer GenomicsGeneticsHuman Genome
Project Terms
AcetylationAcetyltransferaseAddressAmplifiersApoptosisBindingBiochemicalBiological ProcessCancer BiologyCancer Cell GrowthCause of DeathCellsChIP-seqComplexDNADNA Binding DomainDNA StructureDataDevelopmentDiagnosisEvolutionGene AmplificationGene ExpressionGene ProteinsGenesGenetic Predisposition to DiseaseGenetic TranscriptionGoalsHelix-Turn-Helix MotifsHistonesHumanLeucine ZippersLinkMYC Family ProteinMalignant NeoplasmsMediatingMediator of activation proteinMethylationMethyltransferaseModelingMutationNormal CellNuclearOncogenicPaperPathway interactionsPhosphotransferasesProteinsPublishingRNA Polymerase IIRepressionRoleSignal PathwayStructureTRRAP geneTransactivationTranscriptional Activationbasec-myc Genescancer therapycell typecofactorgene repressiongenome-wideinhibitor/antagonistinsightmRNA cappingoverexpressionpromoterprotein functionpublic health relevancerecruitresponsetranscription factortranscription factor TFIIHtumor
No Sub Projects information available for 5R01CA055248-26
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA055248-26
Patents
No Patents information available for 5R01CA055248-26
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA055248-26
Clinical Studies
No Clinical Studies information available for 5R01CA055248-26
News and More
Related News Releases
No news release information available for 5R01CA055248-26
History
No Historical information available for 5R01CA055248-26
Similar Projects
No Similar Projects information available for 5R01CA055248-26